ClinicalTrials.gg
CompletedNCT00279747Updated Nov 1, 2013

A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

A Phase 3 interventional study of meloxicam 0.25 mg/kg and meloxicam 0.125 mg/kg in Arthritis, Juvenile Rheumatoid, sponsored by Boehringer Ingelheim. Completed at 34 sites in 7 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 56 studies in Arthritis, Juvenile with a site in Italy — 19 open to participants now, 24 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.

Enrollment
4th of 43
226 · median 90
Started
2000
the only one that year
Phase 3
28 of 56
8 open now
Registered
3rd of 56
by date

Among the 56 studies in Arthritis, Juvenile with a site in Italy, this one is the 4th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2000, is one of 28 in phase 3, and was the 3rd registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

19 of the 56 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Arthritis, Juvenile with a site in Italy, or all of them as a file.
02

Study summary

A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.

Read the detailed description

Objective: In an international, multicenter, double-blind, randomized clinical trial we evaluated the short-term (3 months) and long term (12 months) efficacy and safety of two doses of meloxicam oral suspension compared with naproxen in children with oligo and polyarticular course juvenile idiopathic arthritis (JIA).

Methods: Children with active oligo or polyarticular course JIA, requiring therapy with an NSAID were eligible for this trial. Patients were randomly allocated to therapy with meloxicam oral suspension 0.125 mg/kg body weight in single daily dose, meloxicam 0.25 mg/kg body weight in single daily dose, or naproxen 10 mg/kg body weight in two daily doses. The trial drugs were administered in a double-blind, double-dummy design for up to 12 months. Response rates were determined according to the American College of Rheumatology Pediatric 30% definition of improvement (ACR Ped 30). Safety parameters were assessed by evaluation of the adverse events in the 3 groups.

Study Hypothesis:

The null hypothesis of interest is that the magnitude of response with regard to the primary endpoint is equivalent between the treatment groups. The alternative is that there is any difference (two-sided) between any of the treatment groups.

Comparison(s):

Naproxen oral suspension 10 mg/kg body weight.

03

Conditions studied

  • Arthritis, Juvenile Rheumatoid

Browse trials for

04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients and inpatients aged 2 to 16 years
  • Diagnosis of idiopathic arthritis of childhood by ILAR criteria:

    • Age of onset less than 16 years
    • Arthritis in one or more joints defined as swelling, or - if no swelling is present - limitation in range of joint movement with joint pain or tenderness, which is not due to primary mechanical disorders
    • Duration of the disease > 6 weeks
    • Type of onset of disease during the first 6 months classified as polyarthritis (5 joints or more; rheumatoid factor positive or negative), oligoarthritis (4 joints or fewer) or systemic arthritis
  • Oligoarthritic, extended oligoarthritic or polyarthritic current course of disease
  • Active arthritis as defined above of at least 2 joints
  • At least 2 other abnormal variables of any of the 5 remaining core set parameters. The physician and the parent ratings must be at least 10 mm on a 100 mm VAS scale and the CHAQ score more than 0.
  • Patients requiring therapy with NSAIDs, i.e., the patient fits into one of the following categories:

    • New onset patient
    • Patient in remission, but experiencing a flare and now requiring an NSAID
    • Patient with insufficient therapeutic effect (ITE) or intolerability to another NSAID (other than Naproxen) and now must be changed
  • Written informed permission given by the parent(s) or the subjects legally authorised representative in accordance with local legislation and ICH GCP
  • Active assent given by the patient if the child is capable of understanding the given information (applies to children who have reached an intellectual age of 7 years or greater)

Exclusion criteria

Exclusion Criteria:

  • Patients with systemic course of JRA (intermittent fever with or without rash or other organ involvement) or with current systemic involvement
  • All rheumatic diseases not covered by the inclusion criteria
  • Any finding indicating that the patient has a other disease than JRA at the time of enrollment
  • Patients with abnormal, clinically relevant laboratory values not related to their JRA
  • Pregnancy or breast feeding
  • Women of not using adequate precaution: attention should be drawn to reports that NSAIDs were reported to decrease the effectiveness of intrauterine devices (R95-0164)
  • History of bleeding disorders, gastrointestinal bleeding or cerebrovascular bleeding
  • Active peptic ulcer within the last 6 months
  • Treatment with more than one SAARD/DMARD (slow-acting antirheumatic drug/disease-modifying antirheumatic drug) during the last 3 months prior to study entry
  • Change in treatment with SAARDs/DMARDs during the last 3 months prior to study entry or intended change during the trial duration
  • Change in treatment with during the last month prior to study entry or intended change during the trial duration with exception of local therapy for uveitis
  • One of the following therapies during the last 3 months prior to study entry or their intended use during the trial treatment period

    • Systemic treatment (except for intra-articular injections) with corticosteroids at a dose higher than 10 mg/day or 0.2 mg/kg/day (prednisone equivalent), respectively (whichever is lower)
    • Treatment with hydroxychloroquine at a dose higher than 10 mg/kg/day
    • Treatment with cyclosporine at a dose higher than 5 mg/kg/day
    • Treatment with methotrexate at a dose higher than 15 mg/m2/week
    • Treatment with other cytotoxic agents, gold compounds, D-penicillamine, Enbrel (etanercept), biologic agents and experimentals
  • Intra-articular injections of corticosteroids during the last month prior to study entry and intended injections during the first 4 weeks of the trial treatment period
  • Concomitant administration of other NSAIDs (including topical forms for skin with exception of local therapy for uveitis) or analgesic agents except paracetamol or acetaminophen
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
226 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Response rates according to ACR Ped 30

    Time frame: after 12 weeks of treatment

Secondary outcomes

  1. Global assessment of overall disease activity by investigator

    Time frame: up to 12 months

  2. Parent global assessment of overall well-being

    Time frame: up to 12 months

  3. Assessment of functional disability by means of Childhood Health Assessment Questionnaire (CHAQ)

    Time frame: up to 12 months

  4. Number of joints with active arthritis

    Time frame: up to 12 months

  5. Number of joints with limited range of motion

    Time frame: up to 12 months

  6. Erythrocyte Sedimentation Rate (ESR)

    Time frame: up to 12 months

  7. Parent global assessment of arthritis

    Time frame: up to 12 months

  8. Parent global assessment of pain

    Time frame: up to 12 months

  9. Children's assessment of discomfort

    Time frame: up to 12 months

  10. Change in functional classification (Steinbrocker classification)

    Time frame: up to 12 months

  11. Final global assessment of efficacy by parent

    Time frame: week 12, 12 months

  12. Final global assessment of efficacy by investigator

    Time frame: week 12, 12 months

  13. Withdrawals due to inadequate efficacy

    Time frame: up to 12 months

  14. Paracetamol / acetaminophen consumption

    Time frame: up to 12 months

  15. Final global assessment of tolerability by parent

    Time frame: week 12, 12 months

  16. Final global assessment of tolerability by investigator

    Time frame: week 12, 12 months

  17. Incidence and intensity of adverse events (AEs)

    Time frame: 12 months

  18. Incidence of laboratory adverse events

    Time frame: 12 months

  19. Withdrawal due to adverse event

    Time frame: 12 months

  20. Duration of hospital stay due to gastrointestinal serious adverse event (GI-SAE)

    Time frame: week 12, 12 months

  21. Duration of hospital stay due to adverse events related to trial drug administration

    Time frame: week 12, 12 months

  22. Additional visits to a physician due to gastrointestinal adverse event (GI-AE)

    Time frame: week 12, 12 months

07

Study locations

34 sites
  • Landes-Kinderklinik Linz
    Linz, 4020, Austria
  • Univ.-Klinik für Kinder- und Jugendheilkunde Wien
    Wien, 1090, Austria
  • Gottfried Preyersches Kinderspital d. Stadt Wien
    Wien, 1100 Wien, Austria
  • UZ Gent
    Gent, 9000, Belgium
  • U.Z. Gasthuisberg
    Leuven, 3000, Belgium
  • Boehringer Ingelheim Investigational Site
    Merksem, 2170, Belgium
  • Boehringer Ingelheim Investigational Site
    Angers, France
  • Boehringer Ingelheim Investigational Site
    Lille, France
  • Boehringer Ingelheim Investigational Site
    Marseille, France
  • Boehringer Ingelheim Investigational Site
    Paris, France
  • Boehringer Ingelheim Investigational Site
    Strasbourg, France
  • Boehringer Ingelheim Investigational Site
    Vandoeuvre les Nancy, France
  • Rheumaklinik Bad Bramstedt GmbH
    Bad Bramstedt, 24572, Germany
  • Neurologie
    Bremen, 28325, Germany
  • Universität Erlangen
    Erlangen, 91054, Germany
  • Martin-Luther-Universität Halle
    Halle/Saale, 06097, Germany
  • Boehringer Ingelheim Investigational Site
    Hamburg, 22081, Germany
  • Bayrische Julius-Maximilians-Universität
    Würzburg, 97080, Germany
  • Ospedale Meyer
    Firenze, 50132, Italy
  • Istituto G. Gaslini
    Genova, 16147, Italy
  • Istituto Ortopedico Gaetano Pini
    Milano, 20122, Italy
  • II Università degli Studi di Napoli
    Napoli, 80129, Italy
  • Università Federico II
    Napoli, 80131, Italy
  • Clinica Pediatrica I
    Padova, 35128, Italy
  • IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Ospedale Pediatrico Bambin Gesù
    Roma, 00165, Italy
  • IRCCS Burlo Garofalo
    Trieste, 34137, Italy
  • Institute of Rheumatology of RAMN
    Moscow, 115522, Russian Federation
  • Medical Faculty of Russian People Friendship University
    Moscow, 117049, Russian Federation
  • Scientific Research Institute of Pediatric Hematology
    Moscow, 117513, Russian Federation
  • Medical Academy Setchenov
    Moscow, 119435, Russian Federation
  • Dept. of Child Health
    London, WC1N 3JH, United Kingdom
  • Booth Hall Childrens Hospital
    Manchester, M9 7AA, United Kingdom
  • Paediatric Department
    Wolverhampton, WV10 0QP, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000, a primary completion of Jan 2003 and a completion of Jan 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2006
First posted
Jan 20, 2006
Start
Sep 2000
Primary completionActual
Jan 2003
CompletionActual
Jan 2003
Last update
Nov 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00279747
First posted
Jan 20, 2006
Start date
Sep 2000
Primary completion
Jan 2003
Completion
Jan 2003
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · B.I. Pharma GmbH & Co. KG
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meloxicam · Naproxen

Start the discussion